Kitajima Shojiro, Kudo Yasusei, Ogawa Ikuko, Tatsuka Masaaki, Kawai Hidehiko, Pagano Michele, Takata Takashi
Department of Oral and Maxillofacial Pathobiology, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
PLoS One. 2007 Sep 26;2(9):e944. doi: 10.1371/journal.pone.0000944.
The serine/threonine kinase Aurora-A (Aur-A) is a proto-oncoprotein overexpressed in a wide range of human cancers. Overexpression of Aur-A is thought to be caused by gene amplification or mRNA overexpression. However, recent evidence revealed that the discrepancies between amplification of Aur-A and overexpression rates of Aur-A mRNA were observed in breast cancer, gastric cancer, hepatocellular carcinoma, and ovarian cancer. We found that aggressive head and neck cancers exhibited overexpression and stabilization of Aur-A protein without gene amplification or mRNA overexpression. Here we tested the hypothesis that aberration of the protein destruction system induces accumulation and consequently overexpression of Aur-A in cancer.
Aur-A protein was ubiquitinylated by APC(Cdh1) and consequently degraded when cells exited mitosis, and phosphorylation of Aur-A on Ser51 was observed during mitosis. Phosphorylation of Aur-A on Ser51 inhibited its APC(Cdh1)-mediated ubiquitylation and consequent degradation. Interestingly, constitutive phosphorylation on Ser51 was observed in head and neck cancer cells with protein overexpression and stabilization. Indeed, phosphorylation on Ser51 was observed in head and neck cancer tissues with Aur-A protein overexpression. Moreover, an Aur-A Ser51 phospho-mimetic mutant displayed stabilization of protein during cell cycle progression and enhanced ability to cell transformation.
CONCLUSIONS/SIGNIFICANCE: Broadly, this study identifies a new mode of Aur-A overexpression in cancer through phosphorylation-dependent inhibition of its proteolysis in addition to gene amplification and mRNA overexpression. We suggest that the inhibition of Aur-A phosphorylation can represent a novel way to decrease Aur-A levels in cancer therapy.
丝氨酸/苏氨酸激酶极光激酶A(Aur-A)是一种原癌蛋白,在多种人类癌症中过表达。Aur-A的过表达被认为是由基因扩增或mRNA过表达引起的。然而,最近的证据显示,在乳腺癌、胃癌、肝细胞癌和卵巢癌中,观察到Aur-A基因扩增与Aur-A mRNA过表达率之间存在差异。我们发现侵袭性头颈癌表现出Aur-A蛋白的过表达和稳定,而没有基因扩增或mRNA过表达。在此,我们检验了一种假说,即蛋白质破坏系统的异常会诱导Aur-A在癌症中积累并因此过表达。
当细胞退出有丝分裂时,Aur-A蛋白被后期促进复合体(Cdh1)泛素化并因此降解,并且在有丝分裂期间观察到Aur-A的丝氨酸51位点发生磷酸化。Aur-A丝氨酸51位点的磷酸化抑制了其由后期促进复合体(Cdh1)介导的泛素化及随后的降解。有趣的是,在蛋白过表达和稳定的头颈癌细胞中观察到丝氨酸51位点的组成型磷酸化。事实上,在Aur-A蛋白过表达的头颈癌组织中也观察到丝氨酸51位点的磷酸化。此外,一种Aur-A丝氨酸51磷酸模拟突变体在细胞周期进程中表现出蛋白稳定,并且细胞转化能力增强。
结论/意义:总体而言,本研究除了基因扩增和mRNA过表达外,还通过磷酸化依赖性抑制Aur-A的蛋白水解,确定了癌症中Aur-A过表达的一种新模式。我们认为,抑制Aur-A磷酸化可能是癌症治疗中降低Aur-A水平的一种新方法。